Диссертация (1154718), страница 18
Текст из файла (страница 18)
№ 8 (72). C. 1273–1279.113. Moosbauer C., Morgenstern E., Cuvelier S.L. [et al.]. Eosinophils are a majorintravascular location for tissue factor storage and exposure. // Blood. 2007. № 3(109). C. 995–1002.114. Morita H., Taguchi J., Kurihara H. [et al.]. Genetic polymorphism of 5,10methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary arterydisease. // Circulation. 1997. № 8 (95).
C. 2032–6.115. Myers D.D., Rectenwald J.E., Bedard P.W. [et al.]. Decreased venousthrombosis with an oral inhibitor of P selectin // Journal of Vascular Surgery.2005. № 2 (42). C. 329–336.116. Naess I.A., Christiansen S.C., Romundstad P. [et al.]. Incidence and mortalityof venous thrombosis: a population-based study // Journal of Thrombosis andHaemostasis. 2007. № 4 (5). C. 692–699.117. Niculescu F., Rus H. The role of complement activation in atherosclerosis. //Immunologic research. 2004.
№ 1 (30). C. 73–80.118. Nieto J.A., Camara T., Gonzalez-Higueras E. [et al.]. Clinical outcome ofpatients with major bleeding after venous thromboembolism. Findings from theRIETE Registry. // Thrombosis and haemostasis. 2008. № 5 (100). C. 789–96.119. Nishiuma S., Kario K., Yakushijin K.
[et al.]. Genetic variation in thepromoter region of the beta-fibrinogen gene is associated with ischemic stroke in aJapanese population. // Blood coagulation & fibrinolysis : an international journalin haemostasis and thrombosis. 1998. № 4 (9). C. 373–9.119120. Novikov P., Makarov E., Moiseev S. [et al.]. Venous thromboembolic eventsin systemic vasculitis // Annals of the Rheumatic Diseases. 2015.
№ 3 (74). C. e27.121. Ntatsaki E., Carruthers D., Chakravarty K. [et al.]. BSR and BHPR guidelinefor the management of adults with ANCA-associated vasculitis // Rheumatology.2014. № 12 (53). C. 2306–2309.122. Oger E. Incidence of venous thromboembolism: a community-based study inWestern France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose deBretagne Occidentale. // Thrombosis and haemostasis. 2000. № 5 (83). C. 657–60.123. Ossei-Gerning N., Mansfield M.W., Stickland M.H. [et al.]. Plasminogenactivator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to ahistory of myocardial infarction in patients characterized by coronary angiography.// Arteriosclerosis, thrombosis, and vascular biology.
1997. № 1 (17). C. 33–7.124. Ozkul Y., Evereklioglu C., Borlu M. [et al.]. 5,10-Methylenetetrahydrofolatereductase C677T gene polymorphism in Behcet’s patients with or without ocularinvolvement // British Journal of Ophthalmology. 2005. № 12 (89). C. 1634–1637.125. Panahloo A., Mohamed-Ali V., Gray R.P.
[et al.]. Plasminogen activatorinhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phasereactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI1 gene. // Atherosclerosis. 2003. № 2 (168). C. 297–304.126. Patel K.N., Soubra S.H., Bellera R. V [et al.]. Differential role of vonWillebrand factor and P-selectin on microvascular thrombosis in endotoxemia. //Arteriosclerosis, thrombosis, and vascular biology.
2008. № 12 (28). C. 2225–30.127. Pendergraft W.F., Preston G.A., Shah R.R. [et al.]. Autoimmunity is triggeredby cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.// Nature medicine. 2004. № 1 (10). C. 72–9.128. Poort S.R., Rosendaal F.R., Reitsma P.H. [et al.]. A common genetic variationin the 3’-untranslated region of the prothrombin gene is associated with elevatedplasma prothrombin levels and an increase in venous thrombosis. // Blood. 1996.№ 10 (88). C.
3698–703.129. Prandoni P., Lensing A.W., Cogo A. [et al.]. The long-term clinical course of120acute deep venous thrombosis. // Annals of internal medicine. 1996. № 1 (125). C.1–7.130. Prandoni P., Noventa F., Ghirarduzzi A. [et al.]. The risk of recurrent venousthromboembolism after discontinuing anticoagulation in patients with acuteproximal deep vein thrombosis or pulmonary embolism.
A prospective cohortstudy in 1,626 patients. // Haematologica. 2007. № 2 (92). C. 199–205.131. Pullmann R., Skerenová M., Lukác J. [et al.]. Factor V Leiden andprothrombin G20210A mutations and the risk of atherothrombotic events insystemic lupus erythematosus. // Clinical and applied thrombosis/hemostasis :official journal of the International Academy of Clinical and AppliedThrombosis/Hemostasis. 2004. № 3 (10). C.
233–8.132. Rao A.N., Kazzaz N.M., Knight J.S. Do neutrophil extracellular trapscontribute to the heightened risk of thrombosis in inflammatory diseases? // WorldJournal of Cardiology. 2015. № 12 (7). C. 829.133. Ridker P.M., Hennekens C.H., Miletich J.P. G20210A mutation inprothrombin gene and risk of myocardial infarction, stroke, and venous thrombosisin a large cohort of US men. // Circulation. 1999. № 8 (99).
C. 999–1004.134. Ridker P.M., Hennekens C.H., Selhub J. [et al.]. Interrelation ofhyperhomocyst(e)inemia,factorVLeiden,andriskoffuturevenousthromboembolism. // Circulation. 1997. № 7 (95). C. 1777–82.135. Ridker P.M., Vaughan D.E. Hemostatic factors and the risk of myocardialinfarction. // The New England journal of medicine. 1995. № 6 (333). C.
389;author reply 389-90.136. Rivera J., Lozano M.L., Navarro-Núñez L. [et al.]. Platelet receptors andsignaling in the dynamics of thrombus formation. // Haematologica. 2009. № 5(94). C. 700–11.137. Roach R.E.J., Lijfering W.M., Flinterman L.E. [et al.]. Increased risk of CVDafter VT is determined by common etiologic factors // Blood.
2013. № 24 (121). C.4948–4954.138. Rosendaal F.R., Doggen C.J., Zivelin A. [et al.]. Geographic distribution of121the 20210 G to A prothrombin variant. // Thrombosis and haemostasis. 1998. № 4(79). C. 706–8.139. Rosendaal F.R., Siscovick D.S., Schwartz S.M. [et al.]. A commonprothrombin variant (20210 G to A) increases the risk of myocardial infarction inyoung women. // Blood. 1997. № 5 (90).
C. 1747–50.140. Rothwell P., Coull A., Giles M. [et al.]. Change in stroke incidence, mortality,case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004(Oxford Vascular Study) // The Lancet. 2004. № 9425 (363). C. 1925–1933.141. Sallai K.K., Nagy E., Bodó I. [et al.].
Thrombosis risk in systemic lupuserythematosus: the role of thrombophilic risk factors // Scandinavian Journal ofRheumatology. 2007. № 3 (36). C. 198–205.142. Salomon O., Steinberg D.M., Zivelin A. [et al.]. Single and combinedprothrombotic factors in patients with idiopathic venous thromboembolism:prevalence and risk assessment. // Arteriosclerosis, thrombosis, and vascularbiology.
1999. № 3 (19). C. 511–8.143. Scheven E. von, Lu T.T., Emery H.M. [et al.]. Thrombosis and pediatricWegener’sgranulomatosis:acquiredandgeneticriskfactorsforhypercoagulability. // Arthritis and rheumatism. 2003. № 6 (49). C. 862–5.144. Schmitz C., Lindpaintner K., Verhoef P. [et al.]. Genetic polymorphism ofmethylenetetrahydrofolate reductase and myocardial infarction.
A case-controlstudy. // Circulation. 1996. № 8 (94). C. 1812–4.145. Schouten M., Wiersinga W.J., Levi M. [et al.]. Inflammation, endothelium,and coagulation in sepsis // Journal of Leukocyte Biology. 2007. № 3 (83). C. 536–545.146. Schreiber A., Xiao H., Jennette J.C. [et al.]. C5a receptor mediates neutrophilactivation and ANCA-induced glomerulonephritis.
// Journal of the AmericanSociety of Nephrology : JASN. 2009. № 2 (20). C. 289–98.147. Schulman S., Lindmarker P., Holmstrom M. Post-thrombotic syndrome,recurrence, and death 10 years after the first episode of venous thromboembolismtreated with warfarin for 6 weeks or 6 months // Journal of Thrombosis and122Haemostasis. 2006. № 4 (4). C. 734–742.148. Schwartz S.M., Siscovick D.S., Malinow M.R.
[et al.]. Myocardial infarctionin young women in relation to plasma total homocysteine, folate, and a commonvariant in the methylenetetrahydrofolate reductase gene. // Circulation. 1997. № 2(96). C. 412–7.149. Scott G., Mahdi A.J., Alikhan R. Superficial vein thrombosis: a currentapproach to management // British Journal of Haematology. 2015. № 5 (168). C.639–645.150. Sebastian J.K., Voetsch B., Stone J.H. [et al.].
The frequency ofanticardiolipin antibodies and genetic mutations associated with hypercoagulabilityamong patients with Wegener’s granulomatosis with and without history of athrombotic event. // The Journal of rheumatology. 2007. № 12 (34). C. 2446–50.151. Sevestre M.A., Labarere J., Brin S. [et al.]. [Optimizing history taking forevaluating the risk of venous thromboembolism: the OPTIMEV study]. // Journaldes maladies vasculaires. 2005. № 4 Pt 1 (30). C. 217–27.152.
Shi D.-Y., Wang S.-J. Advances of Coagulation Factor XIII. // Chinesemedical journal. 2017. № 2 (130). C. 219–223.153. Shi D., Xu X., Xu Z. [et al.]. P-selectin: an unpredicted factor for deep veinthrombosis after total hip arthroplasty. // BioMed research international. 2014.(2014). C. 783967.154. Silverstein M.D., Heit J.A., Mohr D.N.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
